Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse

Journal of Neuroimmunology

Volumn 243, Issue 1-2, 2012, Pages 52-55

  Wang, Honghao ^a,b   Wang, Kai ^a   Zhong, Xiaonan ^b   Dai, Yongqiang ^b   Wu, Aimin ^b   Li, Ying ^b   Hu, Xueqiang ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Multiple sclerosis; Neuromyelitis optica; SCD28; SCTLA 4

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENCE RISK; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIGENS, CD28; CHILD; CTLA-4 ANTIGEN; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; RECURRENCE; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84856970594     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.11.010     Document Type: Article

References (24)

1. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 1992, 13:74-76.
2. Cao J., Zhang L., Huang S., Chen P., Zou L., Chen H., Xiang Y., Lai X., Ren G. Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb. Pathog. 2011, 262-267.
3. Espejo C., Brieva L., Ruggiero G., Río J., Montalban X., Martínez-Cáceres E.M. IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 2004, 10:630-635.
4. Fazio R., Radaelli M., Furlan R. Neuromyelitis optica: concepts in evolution. J. Neuroimmunol. 2011, 231:100-104.
5. Gurevich M., Tuller T., Rubinstein U., Or-Bach R., Achiron A. Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med. Genomics 2009, 22(2):46.
6. Hafler D.A., Buchsbaum M., Johnson D., Weiner H.L. Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1985, 18:451-458.
7. Hebbar M., Jeannin P., Magistrelli G., Hatron P.Y., Hachulla E., Devulder B., Bonnefoy J.Y., Delneste Y. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis. Clin. Exp. Immunol. 2004, 136:388-392.
8. Huppert J., Closhen D., Croxford A., White R., Kulig P., Pietrowski E., Bechmann I., Becher B., Luhmann H.J., Waisman A., Kuhlmann C.R. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010, 24:1023-1034.
9. Ip W.K., Wong C.K., Leung T.F., Lam C.W. Plasma concentrations of soluble CTLA-4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children. Pediatr. Pulmonol. 2006, 41:674-682.
10. Kakoulidou M., Wang X., Zhao X., Pirskanen R., Lefvert A.K. Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis. J. Neuroimmunol. 2007, 185:150-161.
11. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13(10):1173-1175.
12. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Fujihara K., Lucchinetti C.F., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction frommultiple sclerosis. Lancet 2004, 364:2106-2112.
13. Lorentzen A.R., Celius E.G., Ekstrøm P.O., Wiencke K., Lie B.A., Myhr K.M., Ling V., Thorsby E., Vartdal F., Spurkland A., Harbo H.F. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. J. Neuroimmunol. 2005, 166:197-201.
14. Magistrelli G., Jeannin P., Herbault N., Benoit De Coignac A., Gauchat J.F., Bonnefoy J.Y., Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 1999, 29:3596-3602.
15. Martins T.B., Rose J.W., Jaskowski T.D., Wilson A.R., Husebye D., Seraj H.S., Hill H.R. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am. J. Clin. Pathol. 2011, 136:696-704.
16. Orabona C., Grohmann U., Belladonna M.L., Fallarino F., Vacca C., Bianchi R., Bozza S., Volpi C., Salomon B.L., Fioretti M.C., Romani L., Puccetti P. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 2004, 5:1134-1142.
17. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
18. Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 2008, 223:143-155.
19. Wang H.H., Dai Y.Q., Qiu W., Lu Z.Q., Peng F.H., Wang Y.G., Bao J., Li Y., Hu X.Q. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 2011, 18:1313-1317.
20. Wiendl H., Neuhaus O., Mehling M., Wintterle S., Schreiner B., Mitsdoerffer M., Wienhold W., Weissert R., Wessels J., Hartung H.P., Weller M., Tolosa E., Melms A. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. J. Neuroimmunol. 2003, 140:177-187.
21. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica. Curr. Treat. Options Neurol. 2008, 10:55-66.
22. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
23. Wong C.K., Lit L.C., Tam L.S., Li E.K., Lam C.W. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:989-494.
24. Zhang J., Raus J. T cell vaccination in multiple sclerosis: hopes and facts. Acta Neurol. Belg. 1994, 94:112-115.